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Abstract
Matrix metalloproteinase 9 (MMP-9) is implicated in var-
ious physiological processes by its ability to degrade the
extracellular matrix (ECM) and process multiple regula-
tory proteins. Normally, MMP-9 expression is tightly con-
trolled in cells. Sustained or enhanced MMP-9 secretion,
however, has been demonstrated to contribute to the
pathophysiology of numerous diseases, including arthri-
tis and tumor progression, rendering this enzyme a major
target for clinical interventions. Here we show that
constitutive MMP-9 secretion was abrogated in THP-1
monocytic leukemia cells by addition of neutralizing anti-
bodies against tumor necrosis factor a (TNF-a) or TNF
receptor type 1 (TNF-R1), as well as by inhibition of TNF-
a converting enzyme (TACE). This indicates that MMP-9
production in these cells is maintained by autocrine
stimulation, with TNF-a acting via TNF-R1. To in-
vestigate the intracellular signaling routes involved in
MMP-9 gene transcription, cells were treated with differ-
ent inhibitors of major mitogen-activated protein kinase
(MAPK) pathways. Interruption of the extracellular signal-
regulated kinase pathway 1/2 (ERK1/2) using PD98059
significantly downregulated constitutive MMP-9 release.
In contrast, blockage of p38 kinase activity by addition
of SB203580 or SB202190, as well as inhibition of c-
Jun N-terminal kinase (JNK) using L-JNK-I1, clearly aug-
mented MMP-9 expression and secretion by an
upregulation of ERK1/2 phosphorylation. Moreover, exo-
genously added TNF-a augmented MMP-9 synthesis
and secretion in THP-1 cells via enhancement of ERK1/
2 activity. Taken together, our results indicate that ERK1/
2 activity plays a pivotal role in TNF-a-induced MMP-9
production and demonstrate its negative modulation by
p38 and JNK activity. These findings suggest ERK1/2
rather than p38 and JNK as a reasonable target to spe-
cifically block MMP-9 expression using MAPK inhibitors
in therapeutic applications.
Keywords: cross-talk; ERK; gelatinase B; JNK;
leukemia; p38.
Introduction
The matrix metalloproteinases (MMPs) constitute a family
of 24 zinc-dependent proteinases that play fundamental
roles in the turnover and remodeling of tissues by
degrading proteins of the extracellular matrix (ECM)
(Sternlicht and Werb, 2001). MMPs have also been impli-
cated in a variety of pathological conditions, including
arthritis (Vincenti and Brinckerhoff, 2002), multiple scle-
rosis (Chandler et al., 1997), and tumor progression (Ege-
blad and Werb, 2002).
The MMPs are divided into several subgroups accord-
ing to their structure and substrate specificity. The two
so-called gelatinases, MMP-9 and MMP-2, are key
enzymes in the degradation of basement membranes
(Stetler-Stevenson, 1990). Recent work has elucidated a
much more complex role of these enzymes provided by
the ability of MMP-9 to cleave the intercellular adhesion
molecule-1 (ICAM-1), to process cytokines, such as
transforming growth factor-b (TGFb), interleukin 8 (IL-8),
and IL-1b, and to enhance the bioavailability of vascular
endothelial growth factor (VEGF) (Schonbeck et al., 1998;
Bergers et al., 2000; Van den Steen et al., 2000; Yu and
Stamenkovic, 2000; Fiore et al., 2002). Because of these
versatile functions, MMP-9 is thought to play important
regulatory roles during the immune response (Opdenak-
ker et al., 2001), in angiogenesis (Hamano et al., 2003),
and in malignant diseases (McCawley and Matrisian,
2001).
After secretion from cells, the proteolytic activity of
MMP-9 is mainly regulated by zymogen activation and
interaction with the tissue inhibitor of metalloprotein-
ase 1 (TIMP-1) (Ramos-DeSimone et al., 1999). MMP-9
gene expression is controlled by a promoter containing
AP-1, PEA3 and NF-kB binding sites that tightly regulate
MMP-9 transcription in response to distinct extracellular
stimuli such as TNF-a and IL-1b (He, 1996; Ries and
Petrides, 1995; Westermarck and Kahari, 1999). TNF-a
is one of the strongest physiological inducers of MMP-9
expression. The biological and cellular effects of TNF-a
are mediated through two cell surface receptors, TNF
receptor type 1 (TNF-R1) and type 2 (TNF-R2). TNF-R1
is stimulated by soluble TNF-a, while TNF-R2 is activated
by the membrane-bound precursor preTNF-a (Hehlgans
and Mannel, 2002). Shedding of preTNF-a from the cell
surface is accomplished by the membrane-associated
TNF-a converting enzyme (TACE) (Black et al., 1997).
Intracellular transmission of TNF-a signaling has been
reported to occur via three major members of the mito-
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gen-activated protein kinases (MAPKs) family: ERK1/2
(extracellular signal-regulated kinase), JNK (c-Jun N-ter-
minal kinase), and p38 (Lewis et al., 1998; Kyriakis and
Avruch, 2001). ERK1/2 is phosphorylated by sequential
activation of the Ras-Raf-MEK1/2 cascade upon stimu-
lation of the cells with mitogen-like epidermal growth fac-
tor (EGF), whereas the pathways of JNK and p38 appear
to be primarily induced by inflammatory cytokines (Baud
and Karin, 2001). Phosphorylation of the MAPKs results
in their translocation to the nucleus, where they modulate
gene expression by phosphorylating targets such as
downstream kinases and transcription factors (Pearson
et al., 2001).
Recent data indicate that inflammatory cells that infil-
trate neoplastic tissues favor tumor growth by secretion
of TNF-a and MMP-9 (Coussens et al., 2000; Coussens
and Werb, 2002). Moreover, breast tumor cells release
TNF-a, which stimulates MMP-9 production in stromal
fibroblasts (Stuelten et al., 2005). Therefore, because of
their multiple regulatory roles, MAPKs have been pro-
posed as valuable targets for anti-cancer and anti-inflam-
matory therapies (Hilger et al., 2002; Waetzig et al., 2002;
Sebolt-Leopold and Herrera, 2004). However, little is
known about specific MAPK signal transduction path-
ways responsible for MMP-9 expression.
We used THP-1 monocytic cells that constitutively
synthesize and secrete MMP-9 to study the implication
of three major MAPK pathways in this process. Our
results indicate complex cross-talk between ERK1/2 on
one hand, and p38 and JNK on the other, regulating
MMP-9 expression in opposite manners. For therapeutic
applications, these data suggest the choice of MAPK
inhibitors should be carefully considered to achieve
MMP-9 downregulation but to avoid induction of MMP-
9 biosynthesis.
Results
Constitutive MMP-9 expression in THP-1 cells is
maintained by autocrine stimulation with TNF-a
THP-1 monocytic leukemia cells were used to assess the
role of potential TNF-a-induced signaling in the consti-
tutive expression of MMP-9. The cells were incubated
under serum-free conditions for 24 h with or without dif-
ferent concentrations of an antibody that is capable of
neutralizing the biological activity of TNF-a. Analysis of
MMP-9 mRNA expression by qRT-PCR showed that
addition of anti-TNF-a antibodies significantly decreased
MMP-9 transcription in a dose-dependent manner (Fig-
ure 1A). Analysis of the conditioned medium by gelatin
zymography revealed that basal secretion of the latent
form of MMP-9 was blocked with increasing concentra-
tions of anti-TNF-a antibody (Figure 1B). These findings
on MMP-9 protein correlate with the mRNA expression
data, indicating that endogenous TNF-a is responsible
for continuous MMP-9 expression and secretion in
THP-1 cells. In contrast to MMP-9, constitutive MMP-2
release was not affected under these conditions (Figure
1B).
To determine which TNF-a receptor is involved in the
autocrine regulation of MMP-9 production, THP-1 cells
were treated with neutralizing monoclonal antibodies
against TNF-R1 or TNF-R2. Quantitative analysis of
MMP-9 mRNA revealed that blockage of TNF-R1 down-
regulated MMP-9 gene transcription much better than
blockage of TNF-R2 (Figure 1C). Consistent with these
data, zymographic analysis of conditioned media show-
ed that treatment of the cells with antibodies against
TNF-R1 abrogated MMP-9 secretion in a dose-depend-
ent manner, whereas antibodies against TNF-R2 had only
a marginal inhibitory effect on MMP-9 release (Figure 1D,
upper panel). Appropriate isotype control antibodies
showed no influence on MMP-9 secretion (Figure 1D,
lower panel).
To investigate whether TACE, which is responsible for
the release of TNF-a from the plasma membrane, is
involved in basal MMP-9 secretion, THP-1 cells were
treated with Ro32-7315, a highly specific inhibitor of
TACE activity (Beck et al., 2002). Zymographic analysis
of secreted enzymes showed that increasing concentra-
tions of Ro32-7315 led to a decrease in MMP-9 release
from the cells (Figure 1E). Ro32-7315 had no cytotoxic
effect at concentrations up to 10 mg/ml as determined
by trypan blue staining of the cells (data not shown).
Autocrine TNF-a-mediated MMP-9 expression is
maintained via ERK1/2 activity
To elucidate the signaling cascades involved in basal
MMP-9 production, we first examined the role of the
ERK1/2 pathway. The cell-permeable inhibitor PD98059
selectively blocks the activity of MEK1/2, which is the
upstream activator of ERK1/2. Incubation of THP-1 cells
with this inhibitor induced a dose-dependent down-
regulation of continuous MMP-9 mRNA expression and
enzyme secretion, as determined by real-time PCR and
zymography, respectively (Figure 2A,B). Maximum inhi-
bition of MMP-9 mRNA expression by 85% was
observed at a concentration of 10 mM PD98059 and was
not further enhanced at a higher inhibitor concentration.
MMP-2 secretion was not affected under these condi-
tions. These data suggest that ERK1/2 activity essentially
contributes to basal production and release of MMP-9 in
THP-1 cells.
Inhibitors of p38 upregulate constitutive MMP-9
expression and secretion
To study potential implication of the p38 MAPK pathway
in constitutive MMP-9 expression, cells were incubated
with SB202190 or SB203580, representing specific inhib-
itors of p38. Both compounds consistently led to an aug-
mentation of MMP-9 mRNA expression and protein
secretion, as determined by qRT-PCR and zymography,
respectively (Figure 3A–D). The stimulatory effect on
MMP-9 production was approximately five- to six-fold at
25 mM SB202190 (Figure 3A,B) and three-fold at 25 mM
SB203580 (Figure 3C,D). MMP-2 secretion was not
affected by either of the inhibitors (Figure 3B,D). Appli-
cation of an inactive p38 MAPK inhibitor analogue
(SB202474) up to a concentration of 25 mM had no influ-
ence on MMP-9 mRNA expression or protein secretion
(data not shown). These findings suggest that p38 activ-
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Figure 1 Neutralizing antibodies against TNF-a and TNF-R1 downregulate MMP-9 synthesis and secretion.
THP-1 cells were incubated for 24 h under serum-free conditions in the presence and absence of different concentrations of antibodies
that (A,B) neutralize soluble TNF-a or (C,D) block TNF-R1 and TNF-R2. (A,C) MMP-9 mRNA was quantified by qRT-PCR and (B,D)
culture supernatants were examined for MMP-9 secretion by zymography. Results of mRNA quantification (A,C) are expressed as a
percentage of the unstimulated control normalized to cyclophilin B and represent one single experiment representative of three
determinations, each performed in triplicate. (E) Cells were incubated with different concentrations of the TACE inhibitor Ro 32-7315
under serum-free conditions. Conditioned media were collected after 24 h and analyzed by zymography.
ity has a negative regulatory effect on the constitutive
MMP-9 production in THP-1 cells.
Inhibition of p38 upregulates MMP-9 expression by
increasing the phosphorylation of ERK1/2
Our results suggest a differential role of ERK1/2 and p38
MAPK activity in the regulation of MMP-9 expression. To
examine the effect of simultaneous inhibition of both
kinases, we added the MEK1/2 inhibitor PD98059 and
the p38 inhibitor SB202190 at optimal effective concen-
trations of 25 mM to the cells. Zymographic analysis of
conditioned media revealed that the combined applica-
tion of these inhibitors resulted in abrogation of MMP-9
secretion similar to the effect of ERK1/2 inhibition alone
(Figure 4A). These results suggest that ERK1/2 activity is
required for the stimulatory effect on MMP-9 expression
achieved by inhibition of p38 activity.
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Figure 2 Inhibition of MEK1/2 blocks basal MMP-9 expression
and secretion.
THP-1 cells were incubated with different concentrations of
PD98059 for 24 h. (A) MMP-9 mRNA expression was analyzed
by qRT-PCR and the results are expressed as a percentage of
the unstimulated control normalized to cyclophilin B. Data rep-
resent one of three independent experiments, each performed
in triplicate. (B) Cell culture supernatants were analyzed by
zymography.
To verify our hypothesis of potential interactions
between the two pathways, we examined the level of
ERK1/2 phosphorylation after incubating the cells with
the p38 inhibitor SB202190. Western blotting analysis of
cell lysates showed a significant increase in the phos-
phorylation of ERK1/2 within a 15–60-min period after
treatment with the p38 inhibitor (Figure 4B, upper panel).
To confirm that equal amounts of protein were loaded in
each lane, we applied antibodies that detected total
ERK1/2, both the phosphorylated and the non-phospho-
rylated protein (Figure 4B, lower panel). These data indi-
cate that stimulation of MMP-9 production induced by
inhibition of p38 is mediated via activation of ERK1/2.
Inhibition of the JNK pathway upregulates
constitutive MMP-9 expression alone and in
combination with inhibition of the p38 pathway
To investigate a potential role of the JNK pathway in
autocrine TNF-a-stimulated MMP-9 expression, THP-1
cells were incubated with the water-soluble cell-perme-
able inhibitor peptide (L)-JNK-I1 that specifically blocks
JNK activity. As a control, cells were also incubated with
a non-inhibitory peptide analog. Inhibition of JNK activity
led to dose-dependent stimulation of MMP-9 mRNA
expression and enzyme secretion. MMP-9 mRNA
expression was enhanced by approximately three-fold at
an inhibitor concentration of 10 mM and ;4.5-fold at an
inhibitor concentration of 25 mM (Figure 5A). Consistent
with the mRNA expression, MMP-9 release was aug-
mented to similar extents in the presence of 10 and
25 mM (L)-JNK-I1, as determined by zymography (Figure
5B). The control peptide exhibited no effect on MMP-9
mRNA or protein at a maximum concentration of 25 mM
(Figure 5A,B). To assess if JNK inhibition did influence
ERK1/2 activity, cells were treated with L-JNK-I1 and
examined for ERK1/2 phosphorylation. Analysis of cell
extracts by Western blotting revealed that blockage of
JNK enhanced phosphorylation of ERK1/2 (Figure 5C).
To clarify whether p38 and JNK cooperate in their stim-
ulating influence on MMP-9 production, THP-1 cells were
treated with the respective inhibitors SB202190 and L-
JNK-I1 alone and in combination at a concentration of
10 mM. Analysis of MMP-9 mRNA expression and
enzyme release showed that combined application of
inhibitors for p38 and JNK enhanced MMP-9 biosynthe-
sis and secretion in an additive manner without affecting
MMP-2 release (Figure 6A,B).
Exogenous addition of TNF-a stimulates MMP-9
expression by activation of the ERK1/2 signal
transduction pathway
To examine the implication of MAPK pathways in soluble
TNF-a-initiated signaling and induction of MMP-9
expression, THP-1 cells were preincubated with or with-
out the MEK1/2 inhibitor PD98059 and subsequently
stimulated by exogenous addition of 50 ng/ml TNF-a.
Western blotting analysis of cell extracts showed that in
the absence of MEK1/2 inhibitor, TNF-a leads to
enhanced phosphorylation of ERK1/2 and p38 as early
as 5 min after treatment, which persisted for at least
60 min (Figure 7A, upper panel). Preincubation with
PD98059 prevented TNF-a-stimulated activation of
ERK1/2, but had no effect on p38 phosphorylation (Fig-
ure 7A, upper panel). To control application of equal
amounts of protein in the samples, total ERK1/2 was also
measured (Figure 7A, lower panel). Analysis of MMP-9
synthesis demonstrated that incubation of THP-1 cells
with TNF-a for 24 h significantly stimulated MMP-9
mRNA expression and protein secretion, which was high-
ly significantly blocked upon preincubation of the cells
with PD98059 (Figure 7B,C). Taken together, our data
demonstrate the importance of the ERK1/2 signaling
pathway for enhanced MMP-9 expression upon exoge-
nous stimulation of THP-1 cells with TNF-a.
Discussion
Based on their central roles in regulating growth and sur-
vival of cells, the growth factor-mediated MAPK signaling
pathways have become interesting targets for the devel-
opment of clinical therapies. For the treatment of cancer,
compounds that block MMP gene transcription by inhi-
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 11:06
Modulation of TNF-a-stimulated MMP-9 expression 73
Article in press - uncorrected proof
Figure 3 Inhibitors of p38 enhance MMP-9 production.
THP-1 cells were treated with different concentrations of the p38 inhibitors (A,B) SB202190 or (C,D) SB203580. (A,C) MMP-9 mRNA
was quantified by qRT-PCR. The data represent one of three independent experiments, each performed in triplicate. Results are
shown as a percentage of the unstimulated control and normalized to cyclophilin B. (B,D) Secretion of gelatinases into the cell culture
supernatants was monitored by zymography.
bition of MAPKs have been proposed as potential anti-
tumor agents (Overall and Lopez-Otin, 2002) and several
MAPK inhibitors have already entered clinical cancer tri-
als (Sebolt-Leopold and Herrera, 2004). Since MMP-9 is
known as a key player in the pathophysiology of tumor
progression (Coussens et al., 2000), the purpose of this
study was to analyze the role of major MAPKs on the
cellular expression and secretion of this enzyme. We
have shown in monocytic leukemia cells that inhibition of
the ERK1/2 pathway blocks autocrine and paracrine
TNF-a-induced MMP-9 production, whereas blockage of
p38 and JNK lead to an augmentation of MMP-9 syn-
thesis and secretion. Our data support the utility of inhib-
itors against the ERK1/2 pathway to target MMP-9 for
therapeutic interventions and suggest that blocking of
other MAPK pathways should be critically examined to
avoid potential opposite effects.
It has been shown that inflammatory mechanisms such
as macrophage infiltration and TNF-a release are corre-
lated with MMP-9 expression, angiogenesis, and tumor
growth (Coussens et al., 2000; Coussens and Werb,
2002). Moreover, the primary source of MMP-9 in many
malignant tumors are inflammatory or stromal cells,
including monocytes/macrophages, neutrophils, and
endothelial cells (Egeblad and Werb, 2002). It can be
hypothesized that targeting MMP-9 production by inhi-
bition of specific MAPK pathways could represent a
possible mechanism to suppress tumor growth and
angiogenesis. In our study, we used THP-1 monocytic
cells, characterized by constitutive release of MMP-9, as
a model system to examine the role of MAPK in MMP-9
gene expression. We found that continuous secretion of
MMP-9 in these cells was mediated by autocrine TNF-a
stimulation via TNF-R1, consistent with previous results
obtained in HL-60 and NB4 leukemic cells (Ries et al.,
1994; Ismair et al., 1998). The importance of released
TNF-a in this context was also shown by others using
the unspecific metalloproteinase inhibitor Marimastat
(Robinson et al., 2002). Applying the specific TACE inhib-
itor Ro32-7315 (Beck et al., 2002), we demonstrated that
TACE activity is essential for autocrine TNF-a-stimulated
MMP-9 expression. Slight impairment of MMP-9 gene
expression was also observed upon blocking of TNF-R2,
which may be caused by ‘ligand passing’ from TNF-R2
to TNF-R1.
Various cytokines and growth factors are known to
activate the ERK1/2 pathway, which controls multiple
cellular processes and is frequently found to be active in
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Figure 4 The p38 blockage-stimulated MMP-9 expression
depends on phosphorylation of ERK1/2.
(A) THP-1 cells were incubated with or without 25 mM of the
MEK1/2 inhibitor PD98059 and the p38 inhibitor SB202190,
alone or in combination. Conditioned media were collected and
gelatinolytic activity was analyzed by zymography. (B) Phospho-
ERK1/2 and total ERK1/2 were examined by Western blotting of
cell extracts after treatment of the cells with 25 mM SB202190
for different time intervals.
Figure 5 Inhibition of JNK augments MMP-9 production and phosphorylation of ERK1/2.
THP-1 cells were incubated for 24 h with or without different concentrations of the JNK inhibitor L-JNK-I1 or 25 mM of a control
peptide. (A) MMP-9 mRNA was monitored by qRT-PCR. The data were normalized to cyclophilin B and are expressed as a percentage
relative to the unstimulated control. Results reflect one of three independent experiments performed in triplicate. (B) Cell culture
supernatants were analyzed by zymography. (C) Cells were treated with 25 mM L-JNK-I1 or the control peptide and lysed after
different time intervals. Phosphorylation and total amount of ERK1/2 were analyzed by Western blotting.
tumor cells (Giehl, 2005; Rennefahrt et al., 2005). As we
have demonstrated here, inhibition of the ERK1/2 path-
way in THP-1 leukemic cells caused a marked decrease
in continuous MMP-9 production, which was maintained
by endogenous TNF-a. Likewise, we investigated HL-60
and NB4 leukemic cells, which are also known to secrete
MMP-9, by autocrine stimulation with TNF-a (Ries et al.,
1994; Ismair et al., 1998). In agreement with our findings
in THP-1 cells, blockage of MEK1/2 activity also down-
regulated constitutive MMP-9 production in both HL-60
and NB4 cells (data not shown in the results section to
avoid redundancy). Furthermore, we demonstrated here
that stimulation of THP-1 cells with exogenous TNF-a
significantly upregulated MMP-9 synthesis and release
by enhanced activity of ERK1/2. Taken together, these
findings indicate that the ERK1/2 pathway plays a central
role in TNF-a-induced MMP-9 expression under both
autocrine and paracrine stimulatory conditions.
Whereas knowledge about the contribution of the
ERK1/2 pathway in TNF-a-initiated gene expression is
limited, abundant information is available on the involve-
ment of NF-kB in this process (MacEwan, 2002; Sanceau
et al., 2002). Recently it was reported that ERK1/2 medi-
ates TNF-a-stimulated MMP-9 expression via NF-kB
activity in human smooth muscle cells (Moon et al.,
2004). Our own unpublished results in THP-1 cells, how-
ever, gave no clear evidence for the implication of NF-kB
in autocrine TNF-a-induced MMP-9 expression, although
the exact role of NF-kB remains to be resolved in detail.
So far, our findings clearly demonstrate that TNF-a-reg-
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 11:06
Modulation of TNF-a-stimulated MMP-9 expression 75
Article in press - uncorrected proof
Figure 6 Combined blockage of p38 and JNK upregulates
MMP-9 production in an additive manner.
THP-1 cells were incubated for 24 h in the absence or presence
of the p38 kinase inhibitor SB202190 and the JNK inhibitor L-
JNK-I1 alone or in combination. (A) MMP-9 mRNA was quanti-
fied by qRT-PCR. The results are expressed as a percentage of
the unstimulated control and normalized to cyclophilin B. Data
represent one of three independent experiments, each per-
formed in triplicate. (B) Cell culture supernatants were analyzed
by zymography.
Figure 7 Exogenously added TNF-a enhances MMP-9 expression via activation of ERK1/2.
THP-1 cells were preincubated for 5 min with or without 25 mM PD98059 and then stimulated by addition of 50 ng/ml TNF-a. (A)
After different time intervals the cells were lysed and phosphorylation of MAPK was analyzed by Western blotting using antibodies
against ERK1/2 in combination with antibodies against p38. (B) mRNA was isolated after 24-h incubation and MMP-9 expression
was quantified by RT-PCR. The results are expressed as a percentage of the unstimulated control and normalized to cyclophilin B.
Data represent one of three independent experiments, each performed in triplicate. (C) MMP-9 secretion was examined by zymo-
graphic analysis of THP-1-conditioned media after a 24-h incubation period.
ulated MMP-9 expression in THP-1 cells is essentially
mediated via ERK1/2 signaling, which is in agreement
with data obtained in endothelial cells (Genersch et al.,
2000), keratinocytes (Holvoet et al., 2003), rat astrocytes
(Arai et al., 2003), and vascular smooth muscle cells
(Moon et al., 2004).
Besides ERK1/2, the JNK and p38 MAPK pathways
are typically activated by TNF-a, thus contributing to var-
ious inflammatory pathophysiologies (Baud and Karin,
2001). Recent data have also suggested a negative reg-
ulatory effect of p38 on the ERK1/2 pathway in THP-1
cells cultivated in serum-containing medium (Numazawa
et al., 2003). When we blocked p38 activity in THP-1
cells under serum-free conditions, we also observed
enhanced ERK1/2 phosphorylation, which resulted in
significant upregulation of MMP-9 gene expression and
protein secretion. These findings indicate that p38 acts
as a negative regulator of MMP-9 expression by influ-
encing ERK1/2 activity in a reciprocal manner, whereas
constitutive MMP-2 expression and release was not influ-
enced at all. As shown in isolated primary monocytes,
lipopolysaccharide (LPS)-stimulated MMP-9 expression
was repressed by inhibition of the ERK1/2 pathway, while
blocking of p38 resulted in enhanced ERK1/2 phospho-
rylation and MMP-9 expression (Lai et al., 2003). This is
in agreement with our findings in THP-1 leukemic mono-
cytic cells, demonstrating the pivotal role of ERK1/2 in
MMP-9 expression and its regulation via p38 MAPK
cross-talk. Moreover, in accordance with our findings on
MMP-9, previous work has also demonstrated a negative
effect of p38 activity via ERK1/2 on MMP-1 and MMP-3
expression in different cell systems (New et al., 2001;
Endo et al., 2003). Thus, taken together, this cross-talk
seems to represent a common phenomenon in the reg-
ulation of gene expression of certain but not all MMPs.
Finally, we were able to demonstrate that JNK activity,
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Figure 8 Schematic depiction showing the possible interaction
of signal transduction pathways involved in the regulation of
autocrine TNF-a-induced MMP-9 synthesis.
Endogenous TNF-a is shed from the cell surface by TACE activ-
ity, which can be prevented by addition of a specific TACE-inhib-
itor (Ro32-7315). Soluble TNF-a binds to TNF-R1, thereby
inducing MMP-9 mRNA transcription and protein secretion. Inhi-
bition of MEK1/2 by PD98059 interrupts intracellular signaling
via the ERK1/2 pathway and blocks MMP-9 mRNA expression.
The kinases p38 and JNK in their activated forms act as negative
regulators of MMP-9 transcription by down-modulating ERK1/2
activity. Blockage of either p38 or JNK by specific inhibitors
leads to an upregulation of MMP-9 synthesis. Thus, complex
cross-talk mechanisms between these MAPK pathways may
allow control and fine tuning of TNF-a-stimulated MMP-9
biosynthesis.
similar to p38, negatively controls ERK1/2 phosphoryla-
tion and thereby regulates MMP-9 biosynthesis. Inter-
estingly, very recent data also indicated a negative
cross-talk by demonstrating that activity of the JNK path-
way suppressed ERK1/2 phosphorylation (Rangaswami
et al., 2005).
As summarized in the proposed cross-talk model
shown in Figure 8, our data clearly demonstrate that inhi-
bition of JNK or p38 upregulates MMP-9 production by
stimulating ERK1/2 in THP-1 cells. This indicates that
ERK1/2 represents a key regulator for MMP-9 expression
in these cells that can be modulated via p38 and JNK,
allowing precise regulation of the synthesis and secretion
of this enzyme in response to extracellular stimuli.
Although MMPs, particularly MMP-9, have been rec-
ognized as a promising target in the treatment of malig-
nant diseases, clinical studies with compounds blocking
MMP activity produced disappointing results and novel
strategies emerged to inhibit the expression of distinct
MMPs (Coussens et al., 2002). Therefore, identification
of intracellular signaling cascades responsible for the
biosynthesis of individual MMPs represents a major chal-
lenge in the development of kinase inhibitors intended for
clinical application. According to our data, inhibitors of
the ERK1/2 signal transduction pathway may be useful
for blocking MMP-9 expression in malignant diseases,
whereas inhibitors of p38 or JNK pathway might evoke
unwanted effects by inducing MMP-9 upregulation. The
latter aspect is of major importance, since compounds
that block p38 or JNK have already entered clinical trials
for treatment of malignant tumors or inflammatory dis-
eases (Kumar et al., 2003; Bogoyevitch et al., 2004).
Materials and methods
Antibodies and reagents
Monoclonal neutralizing antibodies against TNF-a, TNF-R1,
TNF-R2, and control antibodies IgG1 and IgG2A were purchased
from R&D Systems (Wiesbaden-Nordenstadt, Germany). The fol-
lowing antibodies were used for Western blotting: anti-ERK1/2,
anti-phospho-ERK1/2, anti-phospho-p38 and anti-mouse IgG-
HRP (all purchased from Cell Signaling Technology Inc., Beverly,
MA, USA). Soluble TNF-a was obtained from PAN systems
(Nu¨rnberg, Germany). Inhibitors used were as follows:
SB203580, SB202190, SB202474, PD98059, cell-permeable
JNK-inhibitor (L-form), negative control for cell-permeable JNK-
inhibitor (L-form), (all from Calbiochem, Bad Soden, Germany).
The TACE inhibitor Ro32-7315 was kindly provided by Dr. H.W.
Krell (Roche Diagnostics, Penzberg, Germany). Stock solutions
of SB203580, SB202190, SB20474 and PD98059 were prepared
in dimethylsulfoxide (DMSO). All other compounds were dis-
solved in culture medium.
Cell culture and treatment of cells
THP-1 monocytic cells originally derived from a patient with
acute monocytic leukemia were obtained from the German Col-
lection of Microorganisms and Cell Cultures (Braunschweig,
Germany). The cells were cultured in RPMI-1640 supplemented
with 10% fetal calf serum (FCS) (PAA Laboratories, Pasching,
Austria), 100 U/ml penicillin-streptomycin 100 mg/ml, and 2 mM
of glutamine (Biochrom AG, Berlin, Germany) at 378C under a
humidified atmosphere of 5% CO2. For all experiments, the cells
were centrifuged, washed three times with PBS and resuspen-
ded in serum-free RPMI-1640 supplemented with 1%Nutridoma
SP (Roche, Mannheim, Germany). Thereafter, the cells were
counted using a Neubauer chamber and adjusted to a concen-
tration of 1=106 /ml. Cells were left untreated or treated with
concentrations of antibodies, MAPK inhibitors or the respective
control molecules, as indicated in the corresponding figures, fol-
lowed by incubation for 24 h.
Preparation of cell extracts and Western blotting
Cells were lysed in lithium dodecyl sulfate containing buffer
(NuPAGE LDS sample buffer 4=) (Invitrogen GmbH, Karlsruhe,
Germany) and then sonicated on ice for 15 s using a B-12 Bran-
son sonifier (Danbury, CT, USA) fitted with a microtip at an inten-
sity of 7 on the output control. The cell lysates were heated for
5 min at 998C and subjected to SDS-PAGE on a precast 4–12%
Bis-Tris polyacrylamide gel (Invitrogen). See-Blue prestained
standard and Magic Mark (Invitrogen) were used for assess-
ment of Western blotting transfer efficiency and for estimation
of molecular masses, respectively. Proteins were blotted onto
PVDF membranes (Millipore, Schwalbach, Germany) for 60 min
at 250 mA and a maximum of 25 V. After transfer, the mem-
branes were blocked in TBS blocking buffer (137 mM NaCl,
20 mM Tris, pH 7.6) containing 0.1% Tween-20 and 5% non-fat
dry milk powder (Roth, Karlsruhe, Germany) for 1 h before incu-
bation with primary antibodies at a concentration of 0.5 mg/ml
for 24 h.
The membranes were then washed in TBS containing 0.1%
Tween-20 (TBS-Tween buffer) and incubated with horseradish
peroxidase-conjugated secondary antibodies at a dilution of
1:1000 in TBS-Tween buffer for 15 min. Detection of bound anti-
bodies was accomplished using substrate enhanced chemolu-
minescence reagent (ECL system, Amersham Bioscience, Little
Chalfont, UK). For sequential detection of different antigens,
antibodies were removed from the blot by incubating the
membrane in stripping buffer (62.5 mM Tris-HCl, 2% SDS, and
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100 mM 2-mercaptoethanol, pH 6.7) for 45 min at 508C, with
subsequent washing in TBS-Tween buffer.
Gelatin zymography
Cell culture supernatants were analyzed for the presence of
gelatinolytic enzymes by zymographic analysis using precast
10% polyacrylamide minigels containing 0.1% gelatin as sub-
strate (Invitrogen). The samples were mixed 1:1 with a non-
reducing buffer containing 126 mM Tris-HCl, 20% glycerol, 4%
SDS and 0.005% bromophenol blue (Invitrogen). As a marker for
electrophoretic mobility of gelatinases in zymograms, we used
conditioned medium from PMA-treated HT1080 fibrosarcoma
cells (Moll et al., 1990) containing the latent form of MMP-9 (ca.
92 kDa), the latent form of MMP-2 (ca. 72 kDa) and the activated
form of MMP-2 (ca. 66 kDa).
After electrophoresis, gels were washed twice for 15 min in
2.7% Triton X-100 on a rotary shaker to remove SDS and to
allow proteins to renature. The gels were then incubated in a
buffer containing 50 mM Tris, pH 7.5, 200 mM NaCl, 5 mM CaCl2
and 0.2% Brij35 (Invitrogen) for 18 h at 378C. The zymograms
were stained for 90 min with 0.02% Coomassie Blue R-350 in
a 30% methanol/10% acetic acid solution using PhastGel-Blue-
R tablets (Amersham Biosciences, Freiburg, Germany). Zymo-
grams were scanned using a Umax ImageScanner driven by
MagicScan software (Amersham Biosciences).
RNA isolation, reverse transcription polymerase
chain reaction (RT-PCR) and real-time quantitative
RT-PCR (qRT-PCR)
Total RNA from differently treated or untreated cells was extract-
ed using the RNeasy mini kit (Qiagen, Hilden, Germany). Sam-
ples of 1 mg of purified RNA were reverse transcribed using the
First Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche)
according to the manufacturer’s instructions. Reverse transcrip-
tion was performed for 60 min at 428C, followed by incubation
at 998C for 5 min to avoid interference with subsequent reac-
tions. For all experiments we used Lightcycler-FastStart DNA
Master SYBR Green I (Roche). Standards and primers were all
purchased from Search LC (Heidelberg, Germany). The qRT-
PCR was performed on a LightCycler system (Roche). PCR con-
ditions were 958C for 10 min, followed by 35 cycles consisting
of 958C for 10 s, 588C for 10 s (secondary target temperature),
688C for 10 s (target temperature) and 728C for 16 s. RNA levels
of target genes were normalized by the level of the housekeep-
ing gene cyclophilin B, used as an endogenous control to cor-
rect the efficiency of the RT-PCR. Results are expressed as a
percentage of the untreated control.
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